Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Investment Securities (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Gains from Investment Securities for 6 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 63118.15% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, up 67.21%, and an annual FY2025 reading of -$62.8 million, down 2214.39% over the prior year.
  • Gains from Investment Securities was $3.9 million for Q3 2025 at SAB Biotherapeutics, down from $7.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.7 million in Q4 2024 and bottomed at -$7.8 million in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $774897.8, with a median of $7606.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities skyrocketed 39397366.67% in 2023, then plummeted 403284.07% in 2025.
  • Year by year, Gains from Investment Securities stood at $5.6 million in 2021, then tumbled by 100.0% to $12.0 in 2022, then surged by 39397366.67% to $4.7 million in 2023, then surged by 63.21% to $7.7 million in 2024, then crashed by 49.6% to $3.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for SABS at $3.9 million in Q3 2025, $7.5 million in Q2 2025, and -$5.0 million in Q1 2025.